疑似肥大细胞活化综合征伴鼻窦阻塞的患者特征:单中心经验
本文回顾性分析了2017年7月至2019年5月间3位医生(1名变态反应科医生、2名鼻科医生)接诊的192例鼻塞患者,其中32例疑似肥大细胞活化综合征(MCAS)。这32例患者的中位年龄为47岁,24例为女性,中位使用靶向肥大细胞介质的药物数为4种(范围2-7)。14例完成了治疗前后SNOT-22评估,评分从59.8±6.2降至42.8±6.7,差异有统计学意义和临床意义(p=0.0015)。结论认为,采用药物升级和手术的多学科方法可能改善疑似MCAS患者的鼻窦症状生活质量。
要点
- 鼻塞患者若伴有反复发作的严重症状(如潮红、瘙痒、荨麻疹等)且对靶向肥大细胞介质药物有反应,应怀疑MCAS。
- 疑似MCAS患者常合并哮喘、药物/食物过敏及过敏反应史,且多数需要多种药物控制症状。
- 药物和手术治疗均可显著改善SNOT-22评分,平均降低17分。
核心结论
- 对疑似MCAS的鼻窦症状患者,采用药物升级和手术的多学科治疗可能改善生活质量。
- 现行MCAS共识标准(要求发作期类胰蛋白酶较基线升高)可能排除部分可从治疗中获益的个体。
研究设计与样本
- 回顾性 review,纳入2017年7月至2019年5月间3位医生(1名变态反应科医生、2名鼻科医生)接诊的192例鼻塞患者。
- 疑似MCAS标准:(1)除鼻塞外,至少2种反复发作的严重症状(潮红、瘙痒、荨麻疹、血管性水肿、喘息、咽喉肿胀、头痛、低血压、腹泻);(2)对靶向肥大细胞介质的药物有临床反应。
- 生活质量采用22项鼻窦结局测试(SNOT-22)量化。
主要发现
- 32例鼻塞患者疑似MCAS,中位年龄47岁,24/32为女性。
- 13/32有鼻窦手术史,11/32有过敏原免疫治疗史;19/32有哮喘史,10/32有药物过敏史,11/32有食物过敏史,10/32有过敏反应史。
- 靶向肥大细胞活化药物的中位数为4种(范围2-7)。
- 11例患者在充分药物治疗后由鼻科医生建议手术。
- 3/32患者血清类胰蛋白酶升高。
关键数值与推荐
- 14例完成治疗前后SNOT-22(4/14手术,10/14药物治疗)。
- 治疗前SNOT-22评分为59.8±6.2(均值±标准误),治疗后为42.8±6.7,差异有统计学意义和临床意义(p=0.0015)。
- 两组平均降低17分。
临床怎么用
- 对鼻塞伴多系统严重症状且对肥大细胞靶向药物有反应者,应考虑疑似MCAS并进行多学科评估。
- 治疗可采用药物升级和/或手术,以改善生活质量。
- 不应仅依赖类胰蛋白酶升高来排除MCAS,需结合临床标准。
局限性
- 回顾性单中心研究,样本量较小(疑似MCAS仅32例)。
- 仅14例有治疗前后SNOT-22数据,可能存在选择偏倚。
- 疑似MCAS标准基于临床反应,缺乏统一确诊标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mast-cell activation syndrome (MCAS) is increasingly recognized. Sinonasal obstruction is common among these patients. There is a paucity of literature describing the characteristics of MCAS and treatment outcomes. METHODS: Retrospective review of 192 patients with nasal congestion July 2017 to May 2019 among 3 providers (1 allergist, 2 rhinologists) was conducted. Suspected MCAS criteria were as follows: (1) at least 2 recurrent severe symptoms in addition to nasal congestion: flushing, pruritus, urticaria, angioedema, wheezing, throat swelling, headache, hypotension, diarrhea; (2) clinical response to medications that target mast cell mediators. Quality of life (QOL) outcomes were quantified using the 22-item Sino-Nasal Outcome Test (SNOT-22). RESULTS: Thirty-two patients with nasal congestion were suspected of MCAS. The median age was 47 years; 24 of 32 were female; 13 of 32 had prior history of sinonasal surgery and 11 of 32 allergen immunotherapy. Out of 32, 19 had history of asthma, 10 drug allergy, 11 food allergy, and 10 anaphylaxis. The median number of medications targeting mast cell activation was 4 (range, 2-7). Eleven patients were offered surgery by a rhinologist after adequate medical management. Three of 32 patients showed elevation of serum tryptase. Fourteen completed pretreatment and posttreatment SNOT-22 (4/14 surgery, 10/14 medical management). Pretreatment score was 59.8 ± 6.2 (mean ± standard error [SEM]) and posttreatment score was 42.8 ± 6.7; the difference was statistically and clinically significant (p = 0.0015). Both groups showed a mean 17-point reduction. CONCLUSION: A multidisciplinary approach to the treatment of sinonasal symptoms using both escalation of medical therapy and surgical approaches may improve QOL of patients with suspected MCAS. Consensus criteria for MCAS, which includes elevation in tryptase over baseline during an episode, may exclude the full spectrum of individuals with MCAS from potentially beneficial treatment.
引用
- Kim JH, Xi S, Ference EH, et al. Patient characteristics of suspected mast-cell activation syndrome with sinonasal obstruction: a single institution experience. Int Forum Allergy Rhinol. 2020. PMID: 32407593. doi:10.1002/alr.22558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。